title: Phospho-tyrosine phosphatase inhibitor Bpv(Hopic) enhances C2C12 myoblast migration in vitro. Requirement of PI3K/AKT and MAPK/ERK pathways.
abstract: Muscle progenitor cell migration is an important step in skeletal muscle myogenesis and regeneration. Migration is required for muscle precursors to reach the site of damage and for the alignment of myoblasts prior to their fusion, which ultimately contributes to muscle regeneration. Limited spreading and migration of donor myoblasts are reported problems of myoblast transfer therapy, a proposed therapeutic strategy for Duchenne Muscular Dystrophy, warranting further investigation into different approaches for improving the motility and homing of these cells. In this article, the effect of protein phospho-tyrosine phosphatase and PTEN inhibitor BpV(Hopic) on C2C12 myoblast migration and differentiation was investigated. Applying a wound healing migration model, it is reported that 1 μM BpV(Hopic) is capable of enhancing the migration of C2C12 myoblasts by approximately 40 % in the presence of myotube conditioned media, without significantly affecting their capacity to differentiate and fuse into multinucleated myotubes. Improved migration of myoblasts treated with 1 μM BpV(Hopic) was associated with activation of PI3K/AKT and MAPK/ERK pathways, while their inhibition with either LY294002 or UO126, respectively, resulted in a reduction of C2C12 migration back to control levels. These results propose that bisperoxovanadium compounds may be considered as potential tools for enhancing the migration of myoblasts, while not reducing their differentiation capacity and underpin the importance of PI3K/AKT and MAPK/ERK signalling for the process of myogenic progenitor migration.
authors.affiliation: Institute for Biomedical Research into Human Movement and Health IRM, Faculty of Science and Engineering, Manchester Metropolitan University, John Dalton Building, Oxford Road, Manchester, UK. gdimchev@uni-bonn.de
authors.forename: Georgi A
authors.initials: GA
authors.lastname: Dimchev
authors.forename: Nasser
authors.initials: N
authors.lastname: Al-Shanti
authors.forename: Claire E
authors.initials: CE
authors.lastname: Stewart
mesh_terms: D000818:Animals; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D051379:Mice; D032446:Myoblasts / Q000166:cytology / Q000201:enzymology*; D051059:PTEN Phosphohydrolase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; C487757:Pten protein, mouse
references.citation: J Cell Sci. 2012 Dec 15;125(Pt 24):5917-26
references.pmid: 23378019
references.citation: Cell Transplant. 2009;18(7):719-30
references.pmid: 19523340
references.citation: Nature. 1994 Mar 31;368(6470):406-7
references.pmid: 8133885
references.citation: J Biol Chem. 2004 Dec 24;279(52):54862-71
references.pmid: 15496413
references.citation: J Cell Mol Med. 2001 Jan-Mar;5(1):33-47
references.pmid: 12067449
references.citation: Int J Biochem Cell Biol. 2007;39(6):1177-89
references.pmid: 17433758
references.citation: Am J Physiol Lung Cell Mol Physiol. 2012 Feb 1;302(3):L287-99
references.pmid: 22037358
references.citation: Mol Ther. 2007 May;15(5):867-77
references.pmid: 17387336
references.citation: Dev Dyn. 1997 Apr;208(4):505-15
references.pmid: 9097022
references.citation: J Muscle Res Cell Motil. 2000 Apr;21(3):223-33
references.pmid: 10952170
references.citation: FASEB J. 2007 Nov;21(13):3573-83
references.pmid: 17601985
references.citation: Muscle Nerve. 1996 Jul;19(7):853-60
references.pmid: 8965839
references.citation: Nat Med. 1997 Sep;3(9):970-7
references.pmid: 9288722
references.citation: J Muscle Res Cell Motil. 1996 Feb;17(1):37-43
references.pmid: 8740430
references.citation: Neuromuscul Disord. 2011 Jan;21(1):4-12
references.pmid: 21055938
references.citation: Cell Physiol Biochem. 2011;27(6):625-36
references.pmid: 21691080
references.citation: Am J Respir Crit Care Med. 2006 Jan 1;173(1):112-21
references.pmid: 16179636
references.citation: Cell Biol Int. 2009 Sep;33(9):911-7
references.pmid: 19555769
references.citation: Cell Transplant. 2003;12(1):91-100
references.pmid: 12693669
references.citation: Lancet. 2011 Aug 13;378(9791):595-605
references.pmid: 21784508
references.citation: J Cell Biol. 1998 Nov 30;143(5):1375-83
references.pmid: 9832564
references.citation: Cell Tissue Res. 2012 Jun;348(3):569-78
references.pmid: 22427060
references.citation: Genes Cancer. 2010 Dec;1(12):1170-7
references.pmid: 21779440
references.citation: Int J Biochem Cell Biol. 2006;38(12):2049-63
references.pmid: 16971167
references.citation: Transplantation. 2004 Jun 15;77(11):1741-7
references.pmid: 15201676
references.citation: Br J Pharmacol. 2007 Dec;152(8):1172-84
references.pmid: 17922022
references.citation: Exp Cell Res. 2001 Aug 1;268(1):36-44
references.pmid: 11461116
references.citation: Exp Cell Res. 2011 Dec 10;317(20):2914-24
references.pmid: 22001117
references.citation: J Neuropathol Exp Neurol. 2011 Sep;70(9):770-8
references.pmid: 21865885
references.citation: Mol Ther. 2004 Mar;9(3):475-82
references.pmid: 15038390
references.citation: Dev Dyn. 2002 Mar;223(2):169-79
references.pmid: 11836782
references.citation: FEBS Lett. 2004 May 21;566(1-3):35-8
references.pmid: 15147864
references.citation: Am J Physiol Cell Physiol. 2003 Apr;284(4):C805-15
references.pmid: 12466149
references.citation: Mol Cell Biol. 2000 Jul;20(13):4658-65
references.pmid: 10848592
references.citation: Exp Cell Res. 2000 Aug 1;258(2):279-87
references.pmid: 10896779